Clinical investigator associated with study at Alembic’s bioequivalence unit gets U.S. FDA warning letter
Alembic Pharmaceuticals announced that the U.S. FDA issued a warning letter to a clinical investigator involved in a bioequivalence study at their Vadodara facility. The company stated the issue relates to informed consent documentation rather than data integrity.
Why it matters
Regulatory compliance in pharmaceutical research is critical for maintaining drug safety standards and market access in the United States.
Alembic Pharmaceuticals on Monday said the U.S. Food and Drug Administration (U.S. FDA) has issued a warning letter to the clinical Investigator associated with a bioequivalence study conducted at the company’s bioequivalence facility in Vadodara.
The article reports on a corporate regulatory filing in a factual, non-partisan manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in